Literature DB >> 21220612

Response to temozolomide in patients with metastatic colorectal cancer with loss of MGMT expression: a new approach in the era of personalized medicine?

Einat Shacham-Shmueli, Alexander Beny, Ravit Geva, Arye Blachar, Arie Figer, Dan Aderka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21220612     DOI： 10.1200/JCO.2010.32.0242

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  14 in total

1.  Mapping clinicopathological entities within colorectal mucinous adenocarcinomas: a hierarchical clustering approach.

Authors:  Charly Liddell; Laure Droy-Dupré; Sylvie Métairie; Fabrice Airaud; Christelle Volteau; Stéphane Bezieau; Christian L Laboisse; Jean-François Mosnier
Journal:  Mod Pathol       Date:  2017-04-21       Impact factor: 7.842

2.  A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer.

Authors:  Michael J Pishvaian; Rebecca S Slack; Wei Jiang; A Ruth He; Jimmy J Hwang; Amy Hankin; Karen Dorsch-Vogel; Divyesh Kukadiya; Louis M Weiner; John L Marshall; Jonathan R Brody
Journal:  Cancer       Date:  2018-03-26       Impact factor: 6.860

3.  Different patterns of DNA methylation of the two distinct O6-methylguanine-DNA methyltransferase (O6-MGMT) promoter regions in colorectal cancer.

Authors:  P Mokarram; M Zamani; S Kavousipour; F Naghibalhossaini; C Irajie; M Moradi Sarabi; S V Hosseini
Journal:  Mol Biol Rep       Date:  2012-12-28       Impact factor: 2.316

Review 4.  Role of MGMT as biomarker in colorectal cancer.

Authors:  Alessandro Inno; Giuseppe Fanetti; Maria Di Bartolomeo; Stefania Gori; Claudia Maggi; Massimo Cirillo; Roberto Iacovelli; Federico Nichetti; Antonia Martinetti; Filippo de Braud; Ilaria Bossi; Filippo Pietrantonio
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

5.  MGMT in colorectal cancer: a promising component of personalized treatment.

Authors:  Le Zhang; Jing Zeng; Zhaolei Zeng; Fenghua Wang; Deshen Wang; Cui Chen; Cong Li; Xin An; Ruihua Xu; Peng Huang; Yi Ba; Yuhong Li
Journal:  Tumour Biol       Date:  2016-03-22

6.  Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.

Authors:  Wafik S El-Deiry; Namrata Vijayvergia; Joanne Xiu; Angelique Scicchitano; Bora Lim; Nelson S Yee; Harold A Harvey; Zoran Gatalica; Sandeep Reddy
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

7.  Molecular profiling for personalized cancer care.

Authors:  Raheela Ashfaq
Journal:  Clin Exp Metastasis       Date:  2012-06-08       Impact factor: 5.150

Review 8.  Toward a Molecular Classification of Colorectal Cancer: The Role of MGMT.

Authors:  Parham Minoo
Journal:  Front Oncol       Date:  2013-10-18       Impact factor: 6.244

Review 9.  High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine.

Authors:  Zoran Gatalica; Semir Vranic; Joanne Xiu; Jeffrey Swensen; Sandeep Reddy
Journal:  Fam Cancer       Date:  2016-07       Impact factor: 2.375

Review 10.  Temozolomide in aggressive pituitary adenomas and carcinomas.

Authors:  Leon D Ortiz; Luis V Syro; Bernd W Scheithauer; Fabio Rotondo; Humberto Uribe; Camilo E Fadul; Eva Horvath; Kalman Kovacs
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.